South Korea’s Chungnam National University has come together with prominent biotech company Celltrion to launch a Phase 1 clinical trial of a potential new antiviral antibody treatment for SARS-CoV-2, the virus behind the COVID-19 pandemic
Basis for a Clinical Trial
First, the South Korean-based biotech reported on July 24 that preclinical study generated positive results, and apparently, the Korean Ministry of Food and Drug Safety agreed.
Multiple Clinical Trials Imminent
Chungnam National University will help lead the Phase 1 clinical trial to include 32 patients. Expected to be completed by Q3 2020, the investigational team will evaluate the antiviral antibody treatment candidate’s safety.
Moreover, Celltrion will launch a set of Phase 1 clinical trials targeting mild COVID-19 patients across Europe, followed by a Phase 2 and 3 clinical trial targeting patients with mild and moderate SARS-CoV-2 infections. The company suggested that these studies could be completed by the end of 2020.
In yet another planned clinical trial, Celltrion will seek to investigate the investigational antibody product on people who physically contacted COVID-19 patients globally to study the validity of the potential antiviral antibody treatment and how it may serve to prevent illness. That specific study’s results, at least topline data, are forecast for Q1 2021.
Chungnam National University
Founded in 1952, Chungnam National University is a national university located in Daejeon, South Korea. It is one of ten Flagship Korean National Universities.
Founded in 2002, Celltrion is headquartered in Incheon, South Korea. The company conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. The company’s founder, Jung Jin Seo, is purported to be the second richest person in South Korean